AcquisitionOther
Neurocrine Biosciences, Inc. acquired Soleno Therapeutics, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Neurocrine Biosciences, Inc. -> Soleno Therapeutics, Inc. · $2.9 billion
Expansion of endocrinology and rare disease portfolio with VYKAT XR, first-in-class hyperphagia treatment for Prader-Willi syndrome.
Open source record (SEC) ↗